Disability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Is late-onset myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) associated with a higher risk of time to first relapse or disability compared with adult-onset MOGAD?In this cohort study of 350 adult patients with MOGAD in South Korea, late onset was not uncommon, accounting for 35% of patients. Late onset was not associated with time to first relapse but was independently associated with a higher risk of moderate disability at last follow-up.These findings suggest that patients with late-onset MOGAD may require closer monitoring and early disability-focused interventions.

Corresponding Authors: Su-Hyun Kim, MD, PhD, Department of Neurology, Research Institute and Hospital of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea (herena20@ncc.re.kr); Ju-Hong Min, MD, PhD, Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-gu, Seoul 06351, Korea (juhongm@skku.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.